New collaboration enables faster and more informed drug safety decisions
Boston, MA. – November 06, 2017, – Sciformix Corporation, a leading scientific knowledge-based organization, is proud to announce its adoption of Oracle Argus Enterprise Edition platform to offer superior value to their customers in the Life Science industry. Through its collaboration with Oracle Health Sciences, Sciformix is able to offer its customers a fully automated and integrated safety database solution, allowing easy reporting and analytics for improving the quality and efficiency of drug safety operations. With headquarters in the United States and operations in the United Kingdom, Romania, India and the Philippines, Sciformix partners with Life Sciences clients to provide a full range of services including safety and risk management, clinical development, real world evidence and market access, scientific writing, regulatory affairs and technology services.
The Life Science industry is facing ongoing change with mergers, acquisitions, and increasingly complex regulations, along with the pressure of doing more with less. As a result, organizations have to develop strategies to manage divergent priorities in order to implement cost-saving measures while keeping a keen eye on innovative technology solutions that address growing compliance and data analytics needs. Rapidly growing organizations, with complex safety needs for clinical trials, often lack the necessary technology and scientific knowledge and look to partner with specialized solutions providers to manage their safety data. In addition, well-established companies are looking to increase efficiencies and compliance in the area of post-marketing surveillance. Many of these companies address this by turning to service providers who offer end-to-end solutions so they can focus on their core competencies of developing medicinal products.
In Pharmacovigilance (PV), Sciformix provides adverse event processing services such as safety case intake, medical review of adverse events, regulatory reporting and proactive risk management. Sciformix offers these services leveraging the Argus platform for both customers who utilize its PV services, and companies engaging their own PV delivery model. This offering includes technology infrastructure, user services, application services, regulatory reporting and data analytics. The Argus suite of software solutions enable compliance with E2B exchange standards for expedited reporting, allowing users to conduct global case processing that can scale up to many thousands of annual cases, while also improving reporting capabilities. This comprehensive services offering improves operational efficiencies through individual and bulk case processing, built in audit trails validation, instant scalability, and business agility to meet changing needs, while embracing innovation and reducing IT costs.
On the announcement, Fran Bates, Vice President, Technology Services, Sciformix Corporation commented: “Implementing leading technologies, such as Oracle Argus Enterprise Edition including the Oracle Argus Analytics Platform, will help companies manage their drug safety responsibilities with quality, and easily manage any impending regulatory changes. However, Life Science companies are often reluctant to embrace new technologies due to their perception of risks and costs associated with their adoption. This reluctance is no different in drug safety, but the latest technology being made available as a service minimizes both risk and cost concerns.”
He added: “What’s unique about our full service offering is that it’s end-to-end. Typically, vendors offer specialized services in one area, such as the technology platform, but not user, application and reporting services. Furthermore, Sciformix offers deep functional and domain knowledge that facilitates success in both implementing and managing the Argus drug safety technology platform.”
“Safety is paramount to the clinical research and development agenda, with advanced and robust pharmacovigilance processes and the quality systems crucial for new drug and therapeutic development. Use of a robust safety platform, like Argus, helps consolidate and integrate data across various systems into a single source, helping to track a drug’s real world impact,” said Bruce Palsulich, vice president of safety product strategy for Oracle Health Sciences. “We are excited to see companies like Sciformix leveraging the game-changing technology of Oracle Argus to develop end-to-end PV services for customers globally.”
The Oracle Argus Platform offered through Sciformix enables companies to increase their visibility into their entire risk and safety continuum, including signal management, adverse drug event (ADE) trends, and performance analytics.
To learn more about Sciformix, visit www.sciformix.com , email us at firstname.lastname@example.org, or call us on +1.877.576.5005.
For further press information please contact: Scott Girling-Heathcote, The Scott Partnership: + 44 1477 539539 mail to email@example.com or Susan Najjar, Director of Marketing, Sciformix Corporation: + 1 617-264-0339 mail to firstname.lastname@example.org.
The Oracle Cloud delivers hundreds of SaaS applications and enterprise-class PaaS and IaaS services to customers in more than 195 countries and territories while processing 55 billion transactions a day. For more information about Oracle, please visit us at oracle.com.
Sciformix Corporation is a leading scientific knowledge-based organization that provides process, technology and consulting services to the life sciences industry. We employ best-in-class strategies, technologies and expertise that accelerates business, drives higher levels of performance and fosters innovation. What differentiates Sciformix is our ability to integrate scientific and technology expertise with quality driven processes to provide value to our clients throughout the entire drug development cycle. Our areas of specialization include Safety & Risk Management, Clinical Research & Post-Approval Support Services, Regulatory Affairs & Regulatory Operations, and Technology Services. Corporate headquarters is located in Westborough, MA with operations in the US, EU, India and the Philippines.
We create value for our clients through our singular focus on the life sciences industry, strong pharmaceutical domain competency, exceptional subject matter expertise, uncompromising focus on quality, process rigor, predictable results, and ability to scale. Our portfolio of services spans the full spectrum of product lifecycle from pre-clinical and clinical to post marketing activities to help our customers solve complex analytical challenges, improve the quality of patient healthcare and increase client productivity. For more information, please visit: https://www.sciformix.com/